Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 870

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 870
---

    making
    recommendations to our board of directors regarding corporate governance guidelines.

Our
nominating and corporate governance committee operates under a written charter that satisfies the applicable listing standards of Nasdaq,
a copy of which is available on our website.

Compensation
Committee Interlocks and Insider Participation

None
of the members of our compensation committee is a current or former executive officer or employee of our company. None of our executive
officers serves as a member of the compensation committee of any entity that has one or more executive officers serving on our compensation
committee.

Risk
Oversight

One
of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors administers
this oversight function directly through our board of directors as a whole, and through various standing committees of our board of directors
that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring
and assessing strategic risk exposure, including risks associated with cybersecurity and data protection, and our audit committee has
the responsibility to consider our major financial risk exposures and the steps our management has taken to monitor and control these
exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee
will review legal, regulatory, and compliance matters that could have a significant impact on our financial statements. Our nominating
and corporate governance committee will monitor the effectiveness of our corporate governance practices, including whether they are successful
in preventing illegal or improper liability-creating conduct. Our compensation committee will assess and monitor whether any of our compensation
policies and programs has the potential to encourage excessive risk taking. While each committee is responsible for evaluating certain
risks and overseeing the management of such risks, our entire board of directors will be regularly informed through committee reports
about such risks.

70

Code
of Business Conduct and Ethics

Our
board of directors has adopted a code of business conduct and ethics applicable to all of our directors, officers (including our principal
executive officer, principal financial officer, and principal accounting officer) and all global employees in accordance with applicable
federal securities laws and corporate governance rules of the Nasdaq Capital Market. Our code of business conduct and ethics is available
on our website. Any amendments to the code of business conduct and ethics, or waivers of its requirements, will, if required, be disclosed
on our website.

Insider
Trading Policy

Our
board of directors has adopted an insider trading